PI-RADS 2.1版与2版在移行带前列腺癌读者间变异性和诊断准确性方面的比较
回顾性纳入85例疑似前列腺癌患者,由1名初级和1名高级放射科医生独立使用PI-RADS v2.1和v2评分,以模板引导经会阴前列腺穿刺活检为参考标准。PI-RADS v2.1提高了高级医生诊断临床显著前列腺癌的AUC(0.766 vs 0.902,P=0.009),并提高两名医生的特异度和准确率(均P<0.05)。两版本读者间一致性均良好。
要点
- PI-RADS v2.1可提高高级放射科医生对临床显著移行带前列腺癌的诊断AUC(0.766 vs 0.902,P=0.009)。
- PI-RADS v2.1提高两名医生特异度和准确率,初级医生特异度41.7% vs 78.3%、准确率52.9% vs 76.5%,高级医生特异度33.3% vs 81.7%、准确率48.2% vs 83.5%。
- PI-RADS v2.1中较低类别(PI-RADS 2)前列腺癌百分比降低,较高类别(PI-RADS 3~4)前列腺癌百分比升高。
核心结论
- 与PI-RADS v2相比,PI-RADS v2.1可能改善放射科医生对移行带前列腺癌的诊断性能。
研究设计与样本
- 回顾性纳入2017年1月至12月接受MRI扫描后穿刺活检的85例疑似前列腺癌患者,由1名初级(使用PI-RADS v2经验1年)和1名高级(经验6年)放射科医生独立评分;以模板引导经会阴前列腺穿刺活检为参考标准。
诊断标准与关键数值
- 以PI-RADS≥3为阳性阈值计算敏感度、特异度和准确率;高级医生诊断临床显著前列腺癌的AUC在PI-RADS v2.1为0.902、v2为0.766(P=0.009);初级医生特异度v2.1 78.3% vs v2 41.7%、准确率76.5% vs 52.9%,高级医生特异度81.7% vs 33.3%、准确率83.5% vs 48.2%(均P<0.05)。
临床应用与阅片要点
- PI-RADS v2.1可能改善放射科医生对移行带前列腺癌的诊断性能,尤其提高高级医生的AUC及两名医生的特异度和准确率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare the diagnostic performance of PI-RADS version 2.1 (PI-RADS v2.1) and PI-RADS v2 for transition zone prostate cancer (TZPC), and analyse its performance for readers with different experience levels.
METHODS: Eighty-five patients with suspected prostate cancer who underwent biopsy after MRI scan between January and December 2017 were retrospectively enrolled. One junior radiologist (reader 1, 1 year of experience in using PI-RADS v2) and one senior radiologist (reader 2, 6 years of experience) independently reviewed and assigned a score for each lesion according to PI-RADS v2.1 and v2. The template-guided transperineal prostate biopsy was used for standard of reference. To compare the diagnostic performance of the two methods, the AUC was calculated. The sensitivity, specificity, and accuracy were calculated at predefined positive values (PI-RADS ≥ 3). The interreader agreement and frequency of prostate cancer for each PI-RADS category were also calculated.
RESULTS: Among the 85 patients, 27 had prostate cancers, and 25 were clinically significant prostate cancer (csPCa). The AUC values for diagnosing clinically significant prostate cancer significantly increased with PI-RADS v2.1 for reader 2 (0.766 vs. 0.902, P = 0.009). The specificity and accuracy for both readers also increased with PI-RADS v2.1 (specificity: reader 1, 41.7% vs. 78.3% and reader 2, 33.3% vs. 81.7%; accuracy: reader 1, 52.9% vs. 76.5% and reader 2, 48.2% vs. 83.5%, all P < 0.05). The interreader agreement was good for both versions. The percentage of prostate cancer decreased in lower PI-RADS categories (PI-RADS 2) and increased in higher PI-RADS categories (PI-RADS 3 ~ 4).
CONCLUSION: Compared with PI-RADS v2, PI-RADS v2.1 may improve radiologists' diagnostic performance for TZPC.
引用
- Xu L, Zhang G, Zhang D, et al. Comparison of PI-RADS version 2.1 and PI-RADS version 2 regarding interreader variability and diagnostic accuracy for transition zone prostate cancer. Abdom Radiol (NY). 2020. PMID: 32918577. doi:10.1007/s00261-020-02738-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。